TRANSGENE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.232 EUR | +1.82% |
|
-7.37% | -10.07% |
| 04-10 | Transgene: presents vaccine results at AACR | CF |
| 03-28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Business Summary
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
Number of employees: 143
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Research and Development Collaboration
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -62.12% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
France
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -62.12% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 30/03/22 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 31/03/16 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16/03/16 |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | 31/08/14 |
| Director/Board Member | 63 | 06/12/04 | |
Christophe Ancel
PRN | Corporate Officer/Principal | 60 | - |
Gaëlle Stadtler
HRO | Human Resources Officer | 40 | 13/01/21 |
John Felitti
LAW | General Counsel | 54 | 16/03/16 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 18/06/13 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 31/12/90 |
| Director/Board Member | 63 | 06/12/04 | |
Benoît Habert
BRD | Director/Board Member | 59 | 31/12/99 |
Alessandro Riva
CEO | Chief Executive Officer | 63 | 30/03/22 |
| Director/Board Member | 71 | 31/12/16 | |
Maya Said
BRD | Director/Board Member | 47 | 31/12/16 |
Jean-Yves Blay
BRD | Director/Board Member | 61 | 24/05/22 |
Carol Stuckley
BRD | Director/Board Member | 68 | 04/05/23 |
Sandrine Flory
BRD | Director/Board Member | - | 31/12/20 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 100,852,742 | 34,746,422 ( 34.45 %) | 303,861 ( 0.3013 %) | 34.45 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
TRANSGENE 0.28% | 286,436 | 0.28% | 352,660 $ |
Company contact information
Transgene SA
400, boulevard Gonthier d'Andernach Parc d'Innovation
67405, Strasbourg
+33 3 88 27 91 00
http://www.transgene.fr
Sector
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.21
EUR
Average target price
3.5
EUR
Spread / Average Target
+189.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.07% | 130M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.64% | 22.15B | |
| -17.37% | 21.02B | |
| -8.35% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TNG Stock
- Company Transgene
